|Bid||18.83 x 1400|
|Ask||0.00 x 900|
|Day's Range||17.31 - 19.24|
|52 Week Range||1.75 - 24.70|
|Beta (5Y Monthly)||1.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.00|
Five Prime Announces Closing of Upsized Public Offering of Common Stock
Over the past 10-plus years, biotech stocks have been one of the best areas of the market to unearth hidden gems. Not every small- to mid-cap biotech stock is a proverbial diamond in the rough, however. Most of these equities, in fact, turn out to be duds due to the enormous difficulty of shepherding an experimental drug from the bench to the market.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 12) * ALX Oncology Holdings Inc (NASDAQ: ALXO) * Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Denali Therapeutics Inc (NASDAQ: DNLI) * Eidos Therapeutics Inc (NASDAQ: EIDX) * Fate Therapeutics Inc (NASDAQ: FATE) * Five Prime Therapeutics Inc (NASDAQ: FPRX) (announced preclinical data supporting evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors) * Generation Bio Co (NASDAQ: GBIO) * Guardant Health Inc (NASDAQ: GH) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Inspire Medical Systems Inc (NYSE: INSP) * Insulet Corporation (NASDAQ: PODD) * Kodiak Sciences Inc (NASDAQ: KOD) (announced presentation of clinical study data on its investigational therapy KSI-301 in retinal disorders) * Kura Oncology Inc (NASDAQ: KURA) * MannKind Corporation (NASDAQ: MNKD) * Myokardia Inc (NASDAQ: MYOK) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Oncorus Inc (NASDAQ: ONCR) * OncoSec Medical Inc (NASDAQ: ONCS) * Pacific Biosciences of California Inc (NASDAQ: PACB) * Repligen Corporation (NASDAQ: RGEN) * Shockwave Medical Inc (NASDAQ: SWAV) * Spero Therapeutics Inc (NASDAQ: SPRO) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) (announced its third-quarter results) * Twist Bioscience Corp (NASDAQ: TWST) * Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) * Veracyte Inc (NASDAQ: VCYT)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 12) * Applied Therapeutics Inc (NASDAQ: APLT) (announced its third-quarter results) * Magenta Therapeutics Inc (NASDAQ: MGTA) * Neovasc Inc (NASDAQ: NVCN)Stocks In Focus Urovant Majority Shareholder Buys Remaining Stake It Does Not Already Own In The Biopharma For $16.25/Share Urovant Sciences Ltd (NASDAQ: UROV) said it has entered into a definitive agreement under which Sumitovant Biopharma will acquire Urovant Sciences for $16.25 per share or approximately $584 million in total equity value on a fully diluted basis in an all-cash merger.The per-share price represented a 96% premium over Urovant's closing share price of $8.28 on Nov. 12. During the merger, all Urovant stock, other than those held by Sumitovant, will be canceled and converted into the right to receive $16.25 per share.Sumitovant already owns 72% equity stake in the company.The transaction is expected to close in the first quarter of 2021, subject to approval by the minority shareholders.Urovant shares jumped 90.82% to $15.80 in after-hours trading.Cyclerion Rallies On Insider Buying Cyclerion Therapeutics Inc (NASDAQ: CYCN) revealed in a filing its Chief Innovation Officer Andreas Busch bought 125,000 shares in the company at $2.53 per share. Following the transaction, Busch beneficially owns 254,704 shares in the company.The stock rose 7.66% to $2.67 in after-hours trading.Karyopharm Announces Publication of Positive Xpovio Data In Multiple Myeloma Study Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced publication in the Lancet results of the Phase 3 study evaluating Xpovio in patients with relapsed or refractory multiple myeloma.The BOSTON study evaluated once weekly Xpovio, in combination with once weekly Velcade marketed by Takeda Pharmaceutical Co Ltd (NYSE: TAK) and low-dose dexamethasone against standard twice weekly Velcade in adult patients with multiple myeloma who had received one to three prior lines of therapy.The combo was found to reduce the risk of disease progression or death by 30% and induced a higher rate of overall and deep responses compared to patients receiving a standard twice-weekly Velcade and low-dose dexamethasone regimen.In after-hours session, the stock was up 5.34% to $15.78.Agios Gets Orphan Drug Designation For Drug to Treat Sickle Cell Disease Agios Pharmaceuticals Inc (NASDAQ: AGIO) said the FDA granted orphan drug designation to its first-in-class pyruvate kinase R activator mitapivat for the treatment of patients with sickle cell disease.Innate Pharma Announces Prime Designation Award By European Drug Regulator Innate Pharma SA (NASDAQ: IPHA) said the European Medicines Agency has granted Prime designation to lacutamab, its proprietary first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, for the treatment of patients with relapsed or refractory Sezary syndrome, who have received at least two prior systemic therapies.Earnings Navidea Biopharmaceuticals Inc (NYSE: NAVB) said its third-quarter revenues increased from $237,000 in 2019 to $268,000 in 2020. The loss per share narrowed from 17 cents to 13 cents. Analysts had estimated a loss of 9 cents per share.Updating on its clinical programs, the company said the Phase 2b trial in rheumatoid arthritis is proceeding well, and preparation of package to discuss with the FDA plan for upcoming Phase 3 study is nearing completion.The stock skyrocketed 39.73% to $3.13 in after-hours trading.Biocept Inc's (NASDAQ: BIOC) third-quarter revenues jumped from $1.5 million in 2019 to $6.6 million in 2020, with the increase attributable to RT-PCR COVID-19 testing. The net loss per share narrowed significantly from $2.47 to 43 cents. Analysts had estimated a loss of 47 cents per share.The stock plunged 16.40% to $5.15 in after-hours trading.Opiant Pharmaceuticals Inc (NASDAQ: OPNT) reported third-quarter revenues of $9.1 million, lower than $20.6 million in the year-ago period. The company's net loss per share narrowed from $1.97 to 15 cents. Analysts had modeled a loss of 21 cents per share.In after-hours trading, the stock jumped 10.27% to $8.05.On The Radar PDUFA Dates Sanofi SA (NASDAQ: SNY) awaits FDA nod on its BLA for sutimlimab as a treatment option for hemolysis in adult patients with cold agglutinin disease.Clinical Readouts/Presentations American Academy of Ophthalmology Virtual Meeting Presentations MeiraGTx Holdings PLC (NASDAQ: MGTX): 12-month results from the Phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy for the treatment of X-linked retinitis pigmentosa (5:55 pm) Adverum Biotechnologies Inc (NASDAQ: ADVM): additional clinical data for Cohorts 1-4 in the OPTIC Phase 1 clinical trial of ADVM-022 intravitreal injection gene therapy in wet age-related macular degeneration (2:15 pm)ProQR Therapeutics NV (NASDAQ: PRQR): Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10NGM Biopharmaceuticals Inc (NASDAQ: NGM): detailed Phase 1 safety, tolerability and pharmacokinetics findings from single and multiple intravitreal injections of NGM621 in patients with geographic atrophy (10 am)Regenxbio Inc (NASDAQ: RGNX): a poster presentation on update data on the subretinal RGX-314 gene therapy Phase 1/2a study for the treatment of neovascular AMD and data from preclinical studies of suprachoroidal delivery of RGX-314 (3:36 pm)American Heart Association, or AHA, Scientific Sessions Presentations Cytokinetics, Inc. (NASDAQ: CYTK) and Amgen, Inc. (NASDAQ: AMGN): primary results from the GALACTIC-HFhe Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil in acute heart failureAmerican Association for the Study of Liver Diseases Liver Meeting Presentations NGM Biopharmaceuticals: comprehensive data from its 24-week Phase 2 study (Cohort 4) of aldafermin in patients with non-alcoholic steatohepatitisMetacrine Inc (NASDAQ: MTCR): new Phase 1b data on lead clinical candidate, MET409 for the treatment of non-alcoholic steatohepatitisMadrigal Pharmaceuticals Inc (NASDAQ: MDGL): early data from the Phase 3 MAESTRO study of resmetirom in NASH and data from the MAESTRO-NAFLD-1 open label study (4:30-5 pm)89bio Inc (NASDAQ: ETNB): Phase 1b/2a multiple ascending dose study of BIO89-100 in NASHCymaBay Therapeutics Inc (NASDAQ: CBAY): data from a Phase 2 study of seladelpar in NASHDURECT Corporation (NASDAQ: DRRX): additional safety and efficacy signals from a Phase 1b study of 4-Week Oral DUR-928 in NASH subjectsCan Fite Biopharma ADR Representing 30 Ord Shs (NYSE: CANF): data from the Phase 2, dose-finding study of the efficacy and safety Of namodenoson in treating NAFLD and NASHEiger Biopharmaceuticals Inc (NASDAQ: EIGR): a late-breaker oral presentation of end-of-study results from the LIFT HDV Phase 2 study of peginterferon lambda, lonafarnib, and ritonavir for 24 WeeksEarnings Meridian Bioscience, Inc. (NASDAQ: VIVO) (before the market open) Bio-Path Holdings Inc (NASDAQ: BPTH) (before the market open) AC Immune SA (NASDAQ: ACIU) (before the market open) Checkmate Pharmaceuticals Inc (NASDAQ: CMPI) (before the market open) Prevail Therapeutics Inc (NASDAQ: PRVL) (before the market open) Milestone Pharmaceuticals Inc (NASDAQ: MIST) (before the market open)See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal * The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.